<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268253</url>
  </required_header>
  <id_info>
    <org_study_id>STML-401-0314</org_study_id>
    <nct_id>NCT02268253</nct_id>
  </id_info>
  <brief_title>Tagraxofusp (SL-401) in Patients With CMML or MF</brief_title>
  <official_title>Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML) or Myelofibrosis (MF). [Prior Title: SL-401 in Patients With Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Primary Eosinophilic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia).]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stemline Therapeutics, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stemline Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, multi-arm trial is evaluating the safety and efficacy of tagraxofusp, a&#xD;
      CD123-targeted therapy, in patients with either chronic myelomonocytic leukemia (CMML) or&#xD;
      myelofibrosis (MF). There are two CMML cohorts, one enrolling patients with CMML (CMML-1 or&#xD;
      CMML-2) who are refractory/resistant or intolerant to hypomethylating agents (HMA),&#xD;
      hydroxyurea (HU), or intensive chemotherapy; and one enrolling treatment-naive patients with&#xD;
      CMML (CMML-1 or CMML-2) with molecular features associated with poor prognosis. The MF cohort&#xD;
      will enroll patients who are resistant/refractory or intolerant to approved JAK therapy&#xD;
      (JAK1/JAK2 or JAK2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and severity of treatment-emergent adverse events</measure>
    <time_frame>Through 30 days post last dose of tagraxofusp</time_frame>
    <description>Characterize the safety profile of tagraxofusp in patients with CMML and MF by assessing rates of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of rate of response</measure>
    <time_frame>Through 12 months post last dose of tagraxofusp</time_frame>
    <description>Evaluate the efficacy of tagraxofusp as measured by the rate (%) of response</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Myelofibrosis</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Tagraxofusp (SL-401)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SL-401</intervention_name>
    <arm_group_label>Tagraxofusp (SL-401)</arm_group_label>
    <other_name>tagraxofusp-erzs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Abbreviated Inclusion Criteria:&#xD;
&#xD;
        All Patients (Stages 2 and 3A):&#xD;
&#xD;
          1. The patient is ≥18 years old.&#xD;
&#xD;
          2. The patient has a life expectancy of &gt;6 months.&#xD;
&#xD;
          3. The patient has an Eastern Cooperative Oncology Group (ECOG) performance status (PS)&#xD;
             of 0-2.&#xD;
&#xD;
          4. The patient has adequate baseline organ function, including cardiac, renal, and&#xD;
             hepatic function:&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) ≥ institutional lower limit of normal&#xD;
                  as measured by multigated acquisition scan (MUGA) or 2-dimensional (2-D)&#xD;
                  echocardiogram (ECHO) within 28 days prior to start of therapy and no clinically&#xD;
                  significant abnormalities on a 12-lead electrocardiogram (ECG)&#xD;
&#xD;
               -  Serum creatinine ≤1.5 mg/dL&#xD;
&#xD;
               -  Serum albumin ≥3.2 g/dL (or ≥32 g/L) in the absence of receipt of (IV) albumin&#xD;
                  within the previous 72 hours&#xD;
&#xD;
               -  Bilirubin ≤1.5 mg/dL&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 times the upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               -  Creatine phosphokinase (CPK) ≤2.5 times the ULN&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥0.5 × 10⁹/L&#xD;
&#xD;
        Additional Abbreviated Inclusion Criteria Specific to Patients with MF (Stage 2):&#xD;
&#xD;
          1. Patient meets the 2016 WHO diagnostic criteria for MF and has an IPSS/DIPSS/DIPSS-plus&#xD;
             intermediate-2 or high-risk disease. Patients with IPSS/DIPSS/DIPSS-plus low or&#xD;
             intermediate-1 risk disease who have at least one of the following symptoms are also&#xD;
             eligible: MF-related anemia (Hb &lt;10 g/dL), splenomegaly (palpable size &gt;10 cm),&#xD;
             leukocytosis (WBC &gt;25 × 10⁹/L), marked thrombocytosis (platelet count &gt;1000 × 10⁹/L),&#xD;
             or constitutional symptoms (weight loss &gt;10%, during prior 6 months or fever [&gt;37.5ºC&#xD;
             or drenching night sweats for &gt;6 weeks]), as recommended by the ELN/IWG 2018 criteria.&#xD;
&#xD;
          2. Patient is approved JAK therapy (JAK1/JAK2 or JAK2) resistant/refractory or&#xD;
             intolerant, in accordance with the ELN/IWG 2018 criteria, and at least 4 weeks have&#xD;
             elapsed between the last dose of any MF-directed drug treatments; excluding HU, and&#xD;
             study enrollment (first dose). HU can be continued until 2 weeks prior to study&#xD;
             enrollment.&#xD;
&#xD;
          3. Patient is not eligible for an immediate allo-SCT.&#xD;
&#xD;
        Additional Abbreviated Inclusion Criteria Specific to Patients with CMML (Stage 3A):&#xD;
&#xD;
          1. Patient has a 2016 WHO-defined diagnosis of CMML (persistent monocytosis ≥1 × 10⁹/L&#xD;
             for at least 3 months, with other causes excluded, and monocytes ≥10% of WBC in&#xD;
             peripheral blood, no criteria and no previous history of CML, ET, PV, and acute&#xD;
             promyelocytic leukemia; if eosinophilic, neither PDGFRA, PDGFRB, FGFR1 rearrangements&#xD;
             nor PCM1-JAK2 translocation; &lt;20% blasts in peripheral blood and bone marrow aspirate;&#xD;
             &gt;1 following criteria - dysplasia in &gt;1 myeloid lineage, acquired clonal cytogenetic&#xD;
             or molecular abnormality in hematopoietic cells).&#xD;
&#xD;
          2. Patient has 2016 WHO-defined CMML-1 (2-4% blasts in peripheral blood and/or 5-9%&#xD;
             blasts in bone marrow) and CMML-2 (5-19% blasts in peripheral blood and/or 10-19%&#xD;
             blasts in bone marrow, and/or presence of Auer rods).&#xD;
&#xD;
          3. Patient is refractory/resistant/intolerant to HMAs, or HU, or intensive chemotherapy&#xD;
             OR patient is classified as high-risk based on the presence of morphological features,&#xD;
             as described by the 2016 WHO prognostic system, and the clinical and molecular&#xD;
             features described in molecularly-integrated prognostic systems, such as the GFM, MMM,&#xD;
             and the CMML specific prognostic model (CPSS-Mol), and thus is not expected to benefit&#xD;
             from HMAs.&#xD;
&#xD;
          4. Patient is ineligible for an immediate allo-SCT.&#xD;
&#xD;
        Abbreviated Exclusion Criteria:&#xD;
&#xD;
        All Patients (Stages 2 and 3A):&#xD;
&#xD;
          1. Persistent clinically significant toxicities Grade ≥2 from previous therapies not&#xD;
             readily controlled by supportive measures (excluding alopecia, nausea, and fatigue).&#xD;
&#xD;
          2. Treatment with any disease-related therapy, including radiation therapy or&#xD;
             investigational agent, within 14 days of study entry.&#xD;
&#xD;
          3. Allogeneic SCT within 3 months of study entry.&#xD;
&#xD;
          4. Previous treatment with tagraxofusp or known hypersensitivity to any components of the&#xD;
             drug product.&#xD;
&#xD;
          5. Active malignancy and/or cancer history (excluding myeloproliferative disorders and&#xD;
             concomitant myeloid malignancies as specified in the inclusion criteria) that can&#xD;
             confound the assessment of the study endpoints. Patients with a past cancer history&#xD;
             (within 2 years of entry) and/or ongoing active malignancy or substantial potential&#xD;
             for recurrence must be discussed with the Sponsor before study entry. Patients with&#xD;
             the following neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma&#xD;
             in situ (including superficial bladder cancer), cervical intraepithelial neoplasia, or&#xD;
             organ-confined prostate cancer with no evidence of progressive disease.&#xD;
&#xD;
          6. Clinically significant cardiovascular disease, pulmonary disease, or known active or&#xD;
             suspected disease involvement of the central nervous system (CNS).&#xD;
&#xD;
          7. Receiving immunosuppressive therapy, with the exception of corticosteroids as&#xD;
             specified in the inclusion criteria and tacrolimus, for treatment or prophylaxis of&#xD;
             graft-versus-host disease (GVHD).&#xD;
&#xD;
          8. Uncontrolled intercurrent illness.&#xD;
&#xD;
          9. Patient is pregnant or breast feeding.&#xD;
&#xD;
         10. Patient has known human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C.&#xD;
&#xD;
         11. Patient is oxygen-dependent.&#xD;
&#xD;
        Additional Exclusion Criteria Specific to Patients with MF and CMML (Stages 2 and 3A)&#xD;
        apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stemline Trials</last_name>
    <email>Trials@stemline.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haris Ali, M.D.</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>62684</phone_ext>
      <email>harisali@coh.org</email>
    </contact>
    <investigator>
      <last_name>Haris Ali, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Schiller, MD</last_name>
      <phone>310-825-5513</phone>
      <email>gschiller@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Schiller, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdulraheem Yacoub, M.D.</last_name>
      <phone>913-588-6029</phone>
      <email>ayacoub@kumcc.edu</email>
    </contact>
    <investigator>
      <last_name>Abdulraheem Yacoub, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don A Stevens, MD</last_name>
      <email>Don.Stevens@nortonhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mrinal Patnaik, M.B.B.S.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eunice Wang, MD</last_name>
      <phone>716-845-3544</phone>
      <email>eunice.wang@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Eunice Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sangman Lee, M.D.</last_name>
      <phone>646-962-2700</phone>
      <email>sal9053@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Sangman Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naveen Pemmaraju, M.D.</last_name>
      <phone>713-792-4956</phone>
      <email>npemmaraju@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naveen Pemmaraju, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minakshi Taparia, MD</last_name>
      <phone>780-407-6090</phone>
      <email>mtaparia@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Minakshi Taparia, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikas Gupta, MD</last_name>
      <phone>416-946-4521</phone>
      <email>vikas.gupta@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Vikas Gupta, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 10, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MF</keyword>
  <keyword>CMML</keyword>
  <keyword>CMML-1</keyword>
  <keyword>CMML-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

